Replies to post #61 on Genova Biotherapeutics, Inc.(fka GVBP)

[4keywest]

yesterday it was 50 cents, now its a dollar.
as they say,i'll take half of that.

Hi Everyone,



The September rally seems to have started off great for GVBP! My top stock of the year, GENOVA Biotherapeutics, Inc is already up considerably!


GVBP ran from 0.03 two weeks ago to 0.18 today, that's over 500% and seems to be continuing its bull run.

If the stock continues climbing at this average of 20-30% per day, it will be at well over $1 in the next 2 weeks yielding early investors an ROI of at least 5X.

The question is can it get there? The answer is that odds are in GVBP's favor. The fundamentals are there and recently a few other stocks experienced these types of runs:

TTNP posted up over 5000%
VNDA went from 0.45 to $13 that's over 3000%
CTIC gained more than 4000%

All of the stocks mentioned above are in the same industry as GVBP. The Biotechnology sector is extremely hot and in demand at the moment. Money keeps pouring in from the US government to help these companies achieve tremendous success because as we all know President Obama's policies support Biotechnologies fully.

From a CEO who has worked with companies such as publicly traded Pfizer, Medarex, Myriad Genetics
To massive patent filings for a prostate cancer drug. At this rate we can expect some huge things to come!
To the newly appointed director for Asian business development (notably Korea)

As well as new biotechnologies that could bring in $400 million a year in business for GENOVA once developped.


There seems to be something new and exciting being announced every day. One thing for sure is that GVBP is a very active company with a bright future.


GVBP is likely a once-in-a-lifetime opportunity.

If you have missed out on the other biotechs that soared almost overnight you may want to take a look at GENOVA. The website can be found at: http://genovabio.com and charts also speak for themselves.


Watch GVBP closely tomorrow, it is definitely a symbol you want to have on your radar!


Cheers,
Your CrazyPennyStocks.com editor.

[Epic]

MORE NEWS!!!!!

GVBP HUGE NEWS

GENova files patent for new breast cancer treatment

NEW YORK, NY, Sept 10, 2009 /PRNewswire-FirstCall via COMTEX/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has filed a patent for a potential blockbuster drug target that combats breast cancer.
The target, Tetanolic acid, is a tailor-made lipid which induces cell death in breast cancer cells, thus curtailing development of the harmful cancer.

This novel approach - using proteins to stop cancer - is based on recent discoveries that indicate that most tumors are derived from a cancer stem cell. The technology behind Tetanolic acid involved identifying specific characteristics of these cancer stem cells and then tailoring a lipid (Tetanolic acid) that can identify these characteristics and then attack the malignant cells whilst leaving healthy cells intact. This tailor-made cancer treatment strategy is far superior to any existing therapies, as it terminates the cancer at the source, with no side effects, and no harm to surrounding healthy tissues.

"This target has tremendous market potential, as it can ultimately eliminate the need for surgery and chemotherapy," says Aaron Whiteman for GENova.

Worldwide, breast cancer is the fifth most common cause of cancer death, and is the most common cancer (and cause of cancer death) in women. The demand for new and better treatments for the disease is as urgent as ever.

Whiteman explains GENova's novel approach: "If you compared this disease to a tree, so far, treatments have only treated the crown of the tree - its branches and leaves, and even tried to hit the stem, but no treatment has penetrated its roots. Now that we can identify cancer stem cells, we can remove the root at its formation, and therefore eliminate all sources of life to the tumor. That is the potential behind Tetonolic acid."

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.



www.prnewswire.com
Copyright (C) 2009 PR Newswire. All rights reserved
-0-

KEYWORD: New York
INDUSTRY KEYWORD: MTC